Affiliations 

  • 1 Department of Medicine, University of Malaya Medical Centre, Kuala Lumpur, Malaysia
  • 2 Department of Cardiology, Hospital Serdang, Ministry of Health Malaysia, Selangor, Malaysia
  • 3 Faculty of Medicine, Universiti Teknologi MARA, Selangor, Malaysia
  • 4 Department of Medicine, Hospital Sultanah Bahiyah, Ministry of Health Malaysia, Kedah, Malaysia
  • 5 Department of Medicine, Hospital Kuala Lumpur, Ministry of Health Malaysia, Kuala Lumpur, Malaysia
  • 6 Department of Medicine, Penang General Hospital, Ministry of Health Malaysia, Penang, Malaysia
  • 7 Department of General Medicine and Clinical Research Centre, Hospital Melaka, Ministry of Health Malaysia, Melaka, Malaysia
  • 8 Department of Cardiology, Hospital Sultanah Nur Zahirah, Ministry of Health Malaysia, Terengganu, Malaysia
  • 9 Department of Cardiology, Sarawak Heart Centre, Ministry of Health Malaysia, Sarawak, Malaysia
  • 10 Department of Cardiology, Hospital Raja Permaisuri Bainun, Ministry of Health Malaysia, Perak, Malaysia
  • 11 Department of Cardiology, Hospital Sultanah Aminah, Ministry of Health Malaysia, Johor, Malaysia
  • 12 Department of Cardiology, Hospital Universiti Kebangsaan Malaysia, Ministry of Health Malaysia, Kuala Lumpur, Malaysia
  • 13 Department of General Medicine, Hospital Tengku Ampuan Afzan, Ministry of Health Malaysia, Pahang, Malaysia
  • 14 Department of Cardiology, Hospital Queen Elizabeth II, Ministry of Health Malaysia, Sabah, Malaysia
  • 15 Department of Medical Affairs, Novartis Corporation (Malaysia) Sdn Bhd, Petaling Jaya, Malaysia
  • 16 Department of Cardiology, National Heart Institute of Malaysia, Kuala Lumpur, Malaysia
ESC Heart Fail, 2024 Apr;11(2):727-736.
PMID: 38131217 DOI: 10.1002/ehf2.14608

Abstract

AIMS: Heart failure (HF) is a growing health problem, yet there are limited data on patients with HF in Malaysia. The Malaysian Heart Failure (MY-HF) Registry aims to gain insights into the epidemiology, aetiology, management, and outcome of Malaysian patients with HF and identify areas for improvement within the national HF services.

METHODS AND RESULTS: The MY-HF Registry is a 3-year prospective, observational study comprising 2717 Malaysian patients admitted for acute HF. We report the description of baseline data at admission and outcomes of index hospitalization of these patients. The mean age was 60.2 ± 13.6 years, 66.8% were male, and 34.3% had de novo HF. Collectively, 55.7% of patients presented with New York Heart Association (NYHA) Class III or IV; ischaemic heart disease was the most frequent aetiology (63.2%). Most admissions (87.3%) occurred via the emergency department, with 13.7% of patients requiring intensive care, and of these, 21.8% needed intubation. The proportion of patients receiving guideline-directed medical therapy increased at discharge (84.2% vs. 93.6%). The median length of stay (LOS) was 5 days, and in-hospital mortality was 2.9%. Predictors of LOS and/or in-hospital mortality were age, NYHA class, estimated glomerular filtration rate, and comorbid anaemia. LOS and in-hospital mortality were similar regardless of ejection fraction.

CONCLUSIONS: The MY-HF Registry showed that the HF population in Malaysia is younger, predominantly male, and ischaemic-driven and has good prospects with hospitalization for optimization of treatment. These findings suggest a need to reassess current clinical practice and guide resource allocation to improve patient outcomes.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.